Ozempic, Wegovy, Mounjaro, Zepbound & Rybelsus Lawsuit for Vision Loss (NAION)

Now Reviewing Cases of NAION-Related Blindness Linked to Semaglutide Use

Patients across the U.S. are reporting permanent vision loss after taking GLP-1 weight loss drugs. If you or a loved one developed blindness or NAION after using Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus, you may be entitled to compensation.

Weight Loss Drugs and NAION: A Growing Concern

Medications like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound belong to a class called GLP-1 receptor agonists, originally developed to treat Type 2 diabetes and now widely prescribed for weight loss. While effective for blood sugar control and appetite suppression, these drugs have been linked to a rare but devastating condition:
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).

What Is NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked, causing the nerve to suffer damage or die. Because the optic nerve is responsible for transmitting visual signals from the eye to the brain, this damage often results in permanent, painless vision loss—typically in one eye, though both eyes can be affected in severe cases.

Common NAION symptoms:

• Blurry or dim vision upon waking
• A dark or shadowed area in one eye’s visual field
• Loss of contrast or color sensitivity
• Sudden partial or full vision loss

There is no effective cure or treatment for NAION. In many cases, patients experience permanent vision damage that worsens over time.

The Link Between Semaglutide and Vision Loss

Recent studies and patient reports have raised serious concerns about eye conditions linked to semaglutide and tirzepatide, the active ingredients in many popular weight loss drugs:

• A 2024 Danish/Norwegian cohort study of over 424,000 patients found that semaglutide use more than doubled the risk of NAION, compared to patients taking other diabetes medications like SGLT2 inhibitors.
  
• A 2024 meta-analysis of clinical trials, including Novo Nordisk’s own research, found a higher incidence of optic ischemic neuropathy in patients taking GLP-1 receptor agonists than in placebo groups.
  
• A case series published by Katz et al. documented 7 out of 9 patients on GLP-1 drugs (including Ozempic and Wegovy) who developed NAION or other vision complications.
  

Despite these findings, Novo Nordisk has not updated its U.S. drug labels to include NAION warnings.

Covered Drugs in the NAION Lawsuit

We are currently accepting cases involving vision loss or optic nerve damage related to:

• Ozempic (semaglutide injection)

• Wegovy (semaglutide injection for weight loss)

• Rybelsus (semaglutide oral tablet)

• Mounjaro (tirzepatide injection)

• Zepbound (tirzepatide injection for weight loss)

These drugs are marketed as safe, but the dark side of Ozempic, Wegovy, Mounjaro, and Zepbound is becoming clearer with each new report of eye damage or sudden blindness.

Contact Us Today for a FREE Consultation

If you or a loved one has been injured due to the use of Ozempic, Wegovy, or Rybelsus, don’t wait to seek legal help.

Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.

Call (800) 675-8556 or contact us online to get started. 

Who Qualifies to File a Lawsuit?

You may be eligible if:

• You took Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound
• You developed NAION or experienced sudden, unexplained vision loss
• You sought medical treatment for your vision symptoms
• You have medical records, prescription history, and symptom documentation
• You file within the statute of limitations in your state

Required Documentation

To support your case, you’ll need:

• Pharmacy records showing prescriptions for semaglutide or tirzepatide

• Medical records confirming vision problems or NAION diagnosis

• Imaging or specialist visit records

• Notes from ophthalmologists or neurologists

• Documentation of lost wages, out-of-pocket costs, or reduced quality of life

What Compensation Is Available?

Patients may be entitled to significant compensation for:

• Medical bills and ongoing vision care

• Pain and suffering

• Lost wages and reduced earning capacity

• Emotional trauma and mental anguish

• Loss of independence and life enjoyment

• Permanent disability or blindness-related modifications

Legal Status: Ozempic & Mounjaro Lawsuit Update – June 2025

Attorneys nationwide are now filing lawsuits on behalf of individuals injured by semaglutide and tirzepatide drugs. While not yet consolidated into a multidistrict litigation (MDL), dozens of cases are under review and early settlement discussions are underway.

SSKB is actively building cases and gathering expert medical testimony to support vision loss claims against Novo Nordisk and Eli Lilly.

Statute of Limitations for Filing

Time is limited. Most states have a 2-3 year statute of limitations from the date the injury occurred—or the date you discovered the link to your medication. In New York, the deadline is typically three years, but certain exceptions may apply.

We strongly encourage you to act now to protect your right to sue.

Why Work with Salenger, Sack, Kimmel & Bavaro?

With over four decades of experience in mass tort and product liability litigation, our firm is uniquely positioned to:

• Fight back against major pharmaceutical companies

• Provide personalized legal support at every step

• Work on a contingency-fee basis — you pay nothing unless we win

• Partner with renowned medical experts to strengthen your case

Contact a Vision Loss Lawyer Today

If you suffered NAION, blurry vision, or blindness after using Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, we’re here to help.

📞 Call 800-675-8556 for a free case evaluation
🖊 Or complete our confidential contact form today.